Detection of Group A β-Hemolytic Streptococci in Oral Samples
Primary Purpose
Group A β-Hemolytic Streptococci
Status
Recruiting
Phase
Locations
Israel
Study Type
Observational
Intervention
Collection of oral and/or nasal samples
Sponsored by
About this trial
This is an observational trial for Group A β-Hemolytic Streptococci
Eligibility Criteria
Inclusion Criteria:
- Patient, either male or female, is age 3 years or older;
- Patient is suspected of suffering from GABHS pharyngitis, and is prescribed a throat culture by conventional SOC;
- Patient or legal guardian is able to communicate with study personnel;
- Patient or legal guardian is able to understand oral and written information regarding the nature of the study and is willing to provide written informed consent.
Exclusion Criteria:
- Patients presently on antibiotics prescribed by a physician for treatment or prevention of GAS infection or has taken antibiotics within the past 3 days ( unless patient only first started taking antibiotics within the past 24 hour)
- pregnancy
- Patients who took mouth rinse or taking oral treatment for mouth sores within 3 hours of study
Sites / Locations
- Leumit Healthcare servicesRecruiting
Arms of the Study
Arm 1
Arm Type
Arm Label
oral and/or nasal specimen samples
Arm Description
After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
Outcomes
Primary Outcome Measures
quantify and compare the amount of GABHS
quantify the amount of GABHS contained in different oral and/or nasal sample types collected from patients who have been diagnosed with GABHS pharyngitis
compare the amount of GABHS in different oral and/or nasal samlpes
Compare the amount of GABHS contained in different oral and/or nasal sample types collected from patients who have been diagnosed with GABHS pharyngitis
Secondary Outcome Measures
assess the efficacy of potential GABHS detection methods specifically designed for each oral and/or nasal sample type
to assess the efficacy of potential GABHS detection methods specifically designed for each oral and/or nasal sample type by determining the sensitivity and specificity of each method in compare to the results from standard of care sampeling
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05223634
Brief Title
Detection of Group A β-Hemolytic Streptococci in Oral Samples
Official Title
A Semi-Quantitative and Comparative Study for the Detection of Group A β-Hemolytic Streptococci in Oral Samples
Study Type
Observational
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 18, 2020 (Actual)
Primary Completion Date
June 2022 (Anticipated)
Study Completion Date
June 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hero Scientific
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This prospective, sample collection study will assess different oral and/or nasal sample types collected from patients suspected of suffering from GABHS pharyngitis to conduct research and development on innovative GABHS detection methods specific for each sample type.
Detailed Description
Study candidates are patients age 3 and older with complaints of sore throat and are suspected of suffering from GABHS pharyngitis. Patients who consent and are found eligible will be enrolled in the study. Subjects will be tested according to the conventional standard of care in addition to providing extra specimen samples for the study.
After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected . Study participation is complete once all specimen samples are collected.
Most or all collected samples will be qualitatively tested and may also be quantitatively and/or semi-quantitatively tested for the presence of GABHS. Some collected samples may additionally or alternatively be tested for other respiratory infections as well. (such as SARS-CoV-2, influenza, etc.)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Group A β-Hemolytic Streptococci
7. Study Design
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
oral and/or nasal specimen samples
Arm Description
After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
Intervention Type
Other
Intervention Name(s)
Collection of oral and/or nasal samples
Intervention Description
Collection of oral and/or nasal samples after SOC test performed
Primary Outcome Measure Information:
Title
quantify and compare the amount of GABHS
Description
quantify the amount of GABHS contained in different oral and/or nasal sample types collected from patients who have been diagnosed with GABHS pharyngitis
Time Frame
Study participation ( 1 day participation)
Title
compare the amount of GABHS in different oral and/or nasal samlpes
Description
Compare the amount of GABHS contained in different oral and/or nasal sample types collected from patients who have been diagnosed with GABHS pharyngitis
Time Frame
Study participation ( 1 day participation)
Secondary Outcome Measure Information:
Title
assess the efficacy of potential GABHS detection methods specifically designed for each oral and/or nasal sample type
Description
to assess the efficacy of potential GABHS detection methods specifically designed for each oral and/or nasal sample type by determining the sensitivity and specificity of each method in compare to the results from standard of care sampeling
Time Frame
Study participation ( 1 day participation)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Eligibility Criteria
Inclusion Criteria:
Patient, either male or female, is age 3 years or older;
Patient is suspected of suffering from GABHS pharyngitis, and is prescribed a throat culture by conventional SOC;
Patient or legal guardian is able to communicate with study personnel;
Patient or legal guardian is able to understand oral and written information regarding the nature of the study and is willing to provide written informed consent.
Exclusion Criteria:
Patients presently on antibiotics prescribed by a physician for treatment or prevention of GAS infection or has taken antibiotics within the past 3 days ( unless patient only first started taking antibiotics within the past 24 hour)
pregnancy
Patients who took mouth rinse or taking oral treatment for mouth sores within 3 hours of study
Study Population Description
The study population will be patients aged 3 years and older who are suspected of suffering from GABHS pharyngitis.
Sampling Method
Probability Sample
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Levitz
Phone
+972.2.678.7342
Email
rlevitz@heroscientific.com
First Name & Middle Initial & Last Name or Official Title & Degree
Donna Ehrenberg
Email
donna.ehren@gmail.com
Facility Information:
Facility Name
Leumit Healthcare services
City
Tel Aviv
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ariel Yehuda
Email
aisrael@leumit.co.il
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Detection of Group A β-Hemolytic Streptococci in Oral Samples
We'll reach out to this number within 24 hrs